Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of AG2202 (Tegoprazan) in Healthy Volunteers
NCT06549504Phase 1Not yet recruiting
- Sponsor
- Ahn-Gook Pharmaceutical Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of tegoprazan in gastroesophageal reflux disease (GERD) and gastric ulcer (2 arms), sponsored by Ahn-Gook Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve at 36 hours and Maximum Plasma Concentration at 36 hours. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
tegoprazan
03
Conditions
gastroesophageal reflux disease (GERD)gastric ulcer
Beyond the preview
Go deeper on NCT06549504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06549504.